celecoxib has been researched along with jte 522 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brideau, C; Chan, CC; Charleson, S; Cromlish, W; Ethier, D; Evans, JF; Ford-Hutchinson, AW; Gauthier, JY; Gordon, R; Gresser, M; Guay, J; Kargman, S; Kennedy, B; Leblanc, Y; Léger, S; Mancini, J; O'Neill, GP; Ouellet, M; Percival, MD; Perrier, H; Prasit, P; Riendeau, D; Rodger, I; Wang, Z; Zamboni, R | 1 |
Haruta, J; Hashimoto, H; Imamura, K; Wakitani, K | 1 |
2 other study(ies) available for celecoxib and jte 522
Article | Year |
---|---|
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.
Topics: Administration, Oral; Animals; Biological Availability; CHO Cells; Cricetinae; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Humans; Indomethacin; Inhibitory Concentration 50; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Rats; Sulfones | 1999 |
4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1)
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Benzenesulfonates; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fluorine; Humans; Inhibitory Concentration 50; Isoenzymes; Membrane Proteins; Models, Chemical; Oxazoles; Prostaglandin-Endoperoxide Synthases; Sulfonamides; Temperature | 2002 |